Electrophysiologic Measures of Treatment Response in Alzheimer Disease

This study has been completed.

First Received on July 3, 2001. Last Updated on January 20, 2009 History of Changes

Sponsor:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018278

Purpose

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Condition	Intervention	Phase
Alzheimer Disease	Drug: Aricept Drug: Exelon Drug: Nicoderm Patch	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Drug Information available for: E 2020 Donepezil Rivastigmine SDZ-ENA 713

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 1998
Estimated Study Completion Date:	September 2001

Eligibility

Ages Eligible for Study:	55 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018278

Locations

United States, California
Department of Veterans Affairs
San Diego, California, United States, 92161

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Investigator:	Vincente Iragui, M.D., Ph.D
Investigator:	Shuanna Morris, Ph.D.

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00018278 History of Changes
Other Study ID Numbers:	AGCG-004-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Rivastigmine
Donepezil
Cholinesterase Inhibitors

Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents
Central Nervous System Agents
Therapeutic Uses
Nootropic Agents

ClinicalTrials.gov processed this record on February 12, 2012